Needham Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $16
Needham Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $16
Needham維持對Verrica Pharmicals的買入，將目標股價上調至16美元
Needham analyst Serge Belanger maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and raises the price target from $8 to $16.
Needham分析師塞爾吉·貝蘭格維持Verrica Pharmicals（納斯達克股票代碼：VRCA）的買入並將目標股價從8美元上調至16美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。